𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hearing loss in children with osteogenesis imperfecta

✍ Scribed by Kaija Kuurila; Reidar Grénman; Reijo Johansson; Ilkka Kaitila

Publisher
Springer
Year
2000
Tongue
English
Weight
109 KB
Volume
159
Category
Article
ISSN
0340-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hearing Loss in Children with Osteogenes
Hearing Loss in Children with Osteogenesis Imperfecta (OI) Treated with Bisphosphonates
✍ Christi A. Arnerich; Aaron C. Moberly; Linda A. Dimeglio; Richard T. Miyamoto 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 582 KB

21.4% of children developed hearing loss, a percentage similar to previous population studies. • Since all received treatment, we cannot determine directly bisphosphonate effects on hearing loss over time. • However, it appears that bisphosphonates neither increase hearing loss nor stop progression

Lack of correlation between the type of
Lack of correlation between the type of COL1A1 or COL1A2 mutation and hearing loss in osteogenesis imperfecta patients
✍ Heini Hartikka; Kaija Kuurila; Jarmo Körkkö; Ilkka Kaitila; Reidar Grénman; Sepp 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB

## Communicated by Peter Byers Osteogenesis imperfecta (OI) is caused by mutations in COL1A1 and COL1A2 that code for the a1 and a2 chains of type I collagen. Phenotypes correlate with the mutation types in that COL1A1 null mutations lead to OI type I, and structural mutations in a1(I) or a2(I) lea

Lack of correlation between the type of
Lack of correlation between the type of COL1A1 or COL1A2 mutation and hearing loss in osteogenesis imperfecta patients
✍ Heini Hartikka; Kaija Kuurila; Jarmo Körkkö; Ilkka Kaitila; Reidar Grénman; Sepp 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

The original article to which this Erratum refers was published in Human Mutation 24: 147-154 (2004). In Table 1 of the published original article, the fourth mutation should be c.913G4C (not c.913G4A as originally printed) and it should be bolded as it is a novel mutation. In addition, the last mu